Zacks.com on MSN17h
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating yesterday. David Risinger’s rating is based on several key considerations surrounding ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
Stocktwits on MSN4d
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays StoicShares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback